Clinical Trial Update: Gemcitabine and CT-011 for Resected Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for gemcitabine with CT-011 in resected pancreatic cancer was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms Pancreatic
• Pancreas Cancer
• Pancreatic Cancer
• Pancreatic Neoplasms

Drugs mentioned

• CT-011
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Augusta University | Conditions: Pancreatic Neoplasms, Cancer of the Pancreas | Phase 2 | Status: TERMINATED | Results posted: 2019-07-10